Qdenga Dengue Vaccine in India: Takeda's Guide Explained (2026)

In July 2026, India's drug regulator (DCGI) approved Qdenga — developed by Japanese company Takeda — as the first dengue vaccine cleared for use in India. For families who dread every monsoon fever, platelet count drop, and NS1 report, this is a major public-health milestone.

But approval is not the same as "available at every clinic tomorrow," and a vaccine is not a substitute for mosquito control. This guide explains what Qdenga is, who can take it in India (ages 4 to 60), the two-dose schedule, how well it works, common side effects, who should avoid it, and how it fits with dengue blood tests and hospital care.

If you already have a fever report, see our dengue blood test guide (NS1, platelets, IgM/IgG).

Why Dengue Vaccination Matters in India

Dengue is spread by Aedes mosquitoes (often daytime biters that breed in clean water — flower pots, coolers, tyres, overhead tanks). There are four serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Infection with one type does not permanently protect against the others — and a second infection can sometimes be more severe.

India sees large seasonal surges every monsoon. Cases have risen sharply over the past two decades. Until Qdenga, prevention relied almost entirely on mosquito control and early detection of warning signs — there was no approved dengue vaccine for Indian patients.

What Is Qdenga?

"Live-attenuated" means the vaccine uses weakened forms of the virus that cannot cause normal dengue disease in healthy people, but can train the immune system to recognise dengue later.

Who Can Take Qdenga in India?

As per DCGI approval for India:

How Qdenga differs from older dengue vaccines

An earlier dengue vaccine (Dengvaxia / CYD-TDV) generally required proof of prior dengue infection before vaccination in many settings, because of safety concerns in people who had never had dengue. Qdenga does not require that pre-test, which makes rollout simpler for clinics and families.

Note: WHO programme guidance for public immunisation campaigns has focused especially on children in high-transmission areas (often discussed as ages 6–16). India's product approval covers 4–60. Your doctor will follow the Indian label and local clinical practice when advising you.

Dose Schedule: How Qdenga Is Given

Missing the second dose means you may not get the full protection seen in trials. Put the return date on your calendar the day you take dose 1.

How Effective Is Qdenga?

Large Phase III trials (tens of thousands of participants across Asia and Latin America) found roughly:

Important caveats in plain language:

• Efficacy is not 100% — vaccinated people can still get dengue, usually with lower risk of severe disease/hospitalisation in trial data.
• Protection can be stronger in people who already had dengue (seropositive) than in those who never had it — but Qdenga is still used without mandatory pre-testing.
• Protection varies somewhat by serotype and setting; dengue viruses circulating in your city may differ over time.
• Takeda also ran a Phase III study in India (ages 4–60); the company reported the vaccine was well tolerated and produced an immune response in children, adolescents, and adults.

Qdenga reduces risk — it does not make mosquito bites "safe."

Common Side Effects

Most reactions are mild to moderate and settle in a few days. They tend to be less frequent after the second dose.

Seek urgent care for signs of a severe allergic reaction (difficulty breathing, swelling of face/lips, widespread rash, collapse) — rare but possible with any vaccine.

Who Should Not Take Qdenga? (Contraindications)

Do not take Qdenga if you:

• Are pregnant or breastfeeding
• Have a known severe allergy to a previous dose or any vaccine component
• Have congenital or acquired immunodeficiency
• Are on strong immunosuppressive therapy (for example high-dose steroids for 2+ weeks, chemotherapy, or other drugs that suppress immunity — timing is doctor-decided)
• Have symptomatic HIV, or asymptomatic HIV with impaired immune function

Always disclose medicines, recent illness, and pregnancy plans to your doctor before vaccination. Live vaccines are handled carefully around fertility and transplant patients.

Price and Availability in India

As of the July 2026 DCGI approval announcement:

• Commercial launch date and exact MRP were not yet announced
• Takeda has a manufacturing partnership with Hyderabad-based Biological E aimed at producing up to ~50 million doses per year — which should help supply and, over time, competitive pricing
• Inclusion in government immunisation programmes (if it happens) would further affect access and cost

Until private clinics stock it and pricing is published, ask your paediatrician, physician, or hospital vaccine desk for local availability updates. Do not buy unverified vials online.

Vaccine vs Mosquito Control vs Blood Tests

Best strategy: prevention stack — vaccine (when eligible and available) plus source reduction plus early medical care for fever.

Practical Questions Indian Families Ask

Can I take Qdenga during monsoon if I already had dengue last year?

Usually yes for eligible ages — past infection is not a barrier, and no mandatory pre-test is required. Confirm with your doctor if you are recovering from a recent illness.

Will Qdenga stop me from needing platelet tests if I get fever?

No. Fever still needs clinical evaluation. Vaccinated people can still get dengue; your doctor may still order NS1, CBC, and platelet monitoring based on symptoms.

Is one dose enough before a trip?

No — the studied schedule is two doses, three months apart. Plan ahead; last-minute travel is not a reason to skip dose 2 later.

Is Qdenga in the Universal Immunisation Programme (UIP)?

Not automatically. DCGI approval allows marketing use; national programme inclusion is a separate policy decision. Watch MoHFW / state health updates.

When to See a Doctor After Vaccination or for Dengue Suspicion

Contact a doctor promptly if you have:

• High fever lasting more than 2 days in monsoon season
• Severe abdominal pain, persistent vomiting, bleeding gums, black stools
• Extreme sleepiness, restlessness, cold clammy skin, or rapid breathing
• Falling platelets or rising haematocrit on serial reports

Upload fever-related blood reports to scanura for plain Hindi/English explanations of NS1, platelets, and related values — then follow your doctor's admission advice. scanura does not replace emergency care.

Key Takeaways

1. Qdenga (Takeda) is India's first DCGI-approved dengue vaccine (July 2026).
2. Approved for ages 4 to 60; protects against all four dengue serotypes.
3. Schedule: two subcutaneous doses of 0.5 mL, three months apart.
4. No pre-vaccination dengue blood test is required (unlike some older vaccines).
5. Trial data show strong protection against illness and especially hospitalisation — not 100% prevention.
6. Avoid if pregnant, breastfeeding, or immunocompromised; discuss all medicines with your doctor.
7. Price and nationwide private availability were not fully announced at approval; Biological E manufacturing should support scale.
8. Vaccine does not replace mosquito control or proper testing if fever develops.

Disclaimer: This article is for educational purposes only and reflects publicly reported regulatory and scientific information as of July 2026. Prescribing details, pricing, and programme rollout may change. scanura does not provide medical diagnosis or vaccination services. Always consult a qualified doctor before vaccination or for dengue symptoms.